A total of 19 abstracts at the European Academy of Dermatology Venereology 30th Anniversary Congress will present data for Janssen’s Tremfya (guselkumab), including data showing an improvement in PASI response for psoriasis (PsO) patients who switch to Tremfya® from adalimumab. Mean percentage improvement from baseline in PASI response at week 48 was 94% for guselkumab, compared to 73.4% with adalimumab. At week 252, mean percentage improvement from baseline in PASI response was 92.9% among patients who crossed over at week 48 from adalimumab to guselkumab.

Separate post-hoc analyses of data from the VOYAGE 1 and VOYAGE 2 Phase 3, randomized, double-blind trials comparing guselkumab with placebo and adalimumab in adult patients with moderate to severe plaque psoriasis show that among guselkumab patients who achieved an absolute PASI ≤2 at week 16, durable maintenance of PASI ≤2 was observed through five years.

Through the end of five years, 15% of patients developed anti-drug antibodies (ADA) to guselkumab and of these, 5% (representing 0.8% of all TREMFYA-treated patients) had antibodies that were classified as neutralizing. The development of ADA or neutralizing antibodies were not associated with decreased clinical efficacy or an increase in the incidence of injection site reactions.

There were no reported opportunistic infections or tuberculosis throughout five years of treatment. Serious infections and infection-related treatment-emergent adverse events (TEAEs) of special interest were infrequent.